The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 21, 2019

Filed:

Dec. 28, 2015
Applicant:

Medy-tox, Inc., Chungcheongbuk-do, KR;

Inventors:

Hyun Ho Jung, Seoul, KR;

Gi Hyeok Yang, Chungcheongnam-do, KR;

Hack Woo Kim, Chungcheongnam-do, KR;

Hee Dong Woo, Chungcheongnam-do, KR;

Chang Hoon Rhee, Seoul, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/48 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/22 (2006.01); A61K 8/46 (2006.01); A61K 8/49 (2006.01); A61K 8/66 (2006.01); A61K 47/20 (2006.01); A61Q 19/08 (2006.01); A61K 8/44 (2006.01); A61K 8/64 (2006.01); A61Q 15/00 (2006.01); A61K 47/64 (2017.01);
U.S. Cl.
CPC ...
A61K 38/4893 (2013.01); A61K 8/447 (2013.01); A61K 8/46 (2013.01); A61K 8/4993 (2013.01); A61K 8/64 (2013.01); A61K 8/66 (2013.01); A61K 9/0019 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/64 (2017.08); A61Q 15/00 (2013.01); A61Q 19/08 (2013.01); A61K 2800/52 (2013.01);
Abstract

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without lyophilization process.


Find Patent Forward Citations

Loading…